新辅助-话题@MedSci - williamhill asia

#新辅助#

321篇内容 | 3109人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1678762, encodeId=14be16e876219, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=J Clin Oncol：新辅助治疗可提高早期直肠癌患者的肛门保留率, objectType=article, longId=736336, objectId=bf0fe363366b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf0fe363366b, replyNumber=0, likeNumber=70, createdTime=2022-11-07, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf0fe363366b, moduleTitle=J Clin Oncol：新辅助治疗可提高早期直肠癌患者的肛门保留率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bf0fe363366b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678767, encodeId=122916e8767c4, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗, objectType=article, longId=739152, objectId=0ec4e39152ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec4e39152ac, replyNumber=0, likeNumber=88, createdTime=2023-03-31, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec4e39152ac, moduleTitle=NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0ec4e39152ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678759, encodeId=37e616e87596d, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递, objectType=article, longId=735666, objectId=d837e3566673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d837e3566673, replyNumber=0, likeNumber=77, createdTime=2022-10-17, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d837e3566673, moduleTitle=惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d837e3566673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678764, encodeId=8b7716e87646c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=European Radiology：超声弹性成像在预测乳腺癌新辅助化疗后腋窝淋巴结状态中的应用, objectType=article, longId=736629, objectId=f036e36629ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f036e36629ea, replyNumber=0, likeNumber=62, createdTime=2023-06-04, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f036e36629ea, moduleTitle=European Radiology：超声弹性成像在预测乳腺癌新辅助化疗后腋窝淋巴结状态中的应用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f036e36629ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678765, encodeId=7afe16e8765b2, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=European Radiology：利用深度学习和基于MRI的放射组学列线图自动预测骨肉瘤的新辅助化疗反应, objectType=article, longId=736634, objectId=e196e3663459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e196e3663459, replyNumber=0, likeNumber=118, createdTime=2023-04-01, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e196e3663459, moduleTitle=European Radiology：利用深度学习和基于MRI的放射组学列线图自动预测骨肉瘤的新辅助化疗反应, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e196e3663459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678760, encodeId=7b2c16e87602c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递, objectType=article, longId=735667, objectId=7b4ee35667af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b4ee35667af, replyNumber=0, likeNumber=118, createdTime=2023-06-14, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b4ee35667af, moduleTitle=中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7b4ee35667af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678751, encodeId=f81d16e87518a, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=乳腺癌治疗领域首个免疫检查点抑制剂惨败：T药联合新辅助双妥+化疗未能改善早期乳腺癌pCR！, objectType=article, longId=731017, objectId=9cd7e310174d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cd7e310174d, replyNumber=0, likeNumber=67, createdTime=2023-02-12, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cd7e310174d, moduleTitle=乳腺癌治疗领域首个免疫检查点抑制剂惨败：T药联合新辅助双妥+化疗未能改善早期乳腺癌pCR！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9cd7e310174d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678758, encodeId=24cd16e8758d1, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率, objectType=article, longId=735465, objectId=7ce2e3546529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ce2e3546529, replyNumber=0, likeNumber=102, createdTime=2023-04-30, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ce2e3546529, moduleTitle=Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7ce2e3546529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678747, encodeId=0dae16e8747fc, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=JAMA Oncol：nab-紫杉醇新辅助化疗加用地诺单抗对原发性乳腺癌病理完全缓解率的影响, objectType=article, longId=727710, objectId=a77de27710f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a77de27710f0, replyNumber=0, likeNumber=66, createdTime=2023-04-11, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a77de27710f0, moduleTitle=JAMA Oncol：nab-紫杉醇新辅助化疗加用地诺单抗对原发性乳腺癌病理完全缓解率的影响, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a77de27710f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678749, encodeId=35f016e8749a3, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=European Radiology：基于CESM的放射组学在术前预测乳腺癌新辅助化疗效果方面的价值, objectType=article, longId=728597, objectId=1f74e2859727, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f74e2859727, replyNumber=0, likeNumber=82, createdTime=2022-08-22, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f74e2859727, moduleTitle=European Radiology：基于CESM的放射组学在术前预测乳腺癌新辅助化疗效果方面的价值, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1f74e2859727)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678757, encodeId=f01e16e8757de, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=JAMA Oncol：临界可切除的胰腺导管癌的最佳新辅助治疗策略, objectType=article, longId=732665, objectId=1bb8e32665e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb8e32665e5, replyNumber=0, likeNumber=80, createdTime=2023-05-29, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb8e32665e5, moduleTitle=JAMA Oncol：临界可切除的胰腺导管癌的最佳新辅助治疗策略, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1bb8e32665e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678750, encodeId=aa1d16e8750b6, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=European Radiology：超快速动态增强乳腺MRI在乳腺癌新辅助治疗与病理完全缓解中的应用, objectType=article, longId=728622, objectId=6df5e286222c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6df5e286222c, replyNumber=0, likeNumber=71, createdTime=2022-11-12, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6df5e286222c, moduleTitle=European Radiology：超快速动态增强乳腺MRI在乳腺癌新辅助治疗与病理完全缓解中的应用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6df5e286222c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678738, encodeId=a39c16e873895, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究, objectType=article, longId=723985, objectId=b52ce23985ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b52ce23985ec, replyNumber=0, likeNumber=63, createdTime=2022-07-03, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b52ce23985ec, moduleTitle=AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b52ce23985ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678742, encodeId=07b216e8742ba, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响, objectType=article, longId=724219, objectId=adc4e2421902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adc4e2421902, replyNumber=0, likeNumber=73, createdTime=2023-01-05, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adc4e2421902, moduleTitle=Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=adc4e2421902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678756, encodeId=8ead16e87567f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, objectType=article, longId=732001, objectId=e4e7e32001b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e7e32001b1, replyNumber=0, likeNumber=70, createdTime=2023-03-14, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e7e32001b1, moduleTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e4e7e32001b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678754, encodeId=a7e516e875488, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=European Radiology:平扫MRI定量参数在早期预测乳腺癌新辅助化疗病理反应中的价值, objectType=article, longId=731338, objectId=e4c3e31338f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c3e31338f0, replyNumber=0, likeNumber=58, createdTime=2022-08-09, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c3e31338f0, moduleTitle=European Radiology:平扫MRI定量参数在早期预测乳腺癌新辅助化疗病理反应中的价值, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e4c3e31338f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678735, encodeId=dfe116e87359d, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=European Radiology：MRI对新辅助化疗乳腺癌患者病理完全缓解的预测, objectType=article, longId=723739, objectId=f9e9e23739fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9e9e23739fe, replyNumber=0, likeNumber=66, createdTime=2022-04-10, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9e9e23739fe, moduleTitle=European Radiology：MRI对新辅助化疗乳腺癌患者病理完全缓解的预测, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f9e9e23739fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678718, encodeId=f0e116e871824, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, objectType=article, longId=294716, objectId=db94294e16ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db94294e16ed, replyNumber=0, likeNumber=65, createdTime=2022-02-27, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db94294e16ed, moduleTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=db94294e16ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678766, encodeId=398a16e87666d, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=辅助治疗和新辅助治疗加用免疫治疗在可切除性非小细胞肺癌中的疗效, objectType=article, longId=738390, objectId=0ba4e3839043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ba4e3839043, replyNumber=0, likeNumber=78, createdTime=2023-05-09, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ba4e3839043, moduleTitle=辅助治疗和新辅助治疗加用免疫治疗在可切除性非小细胞肺癌中的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0ba4e3839043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678761, encodeId=7d7316e87611d, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌, objectType=article, longId=736189, objectId=c485e36189fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c485e36189fd, replyNumber=0, likeNumber=71, createdTime=2023-06-30, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c485e36189fd, moduleTitle=J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c485e36189fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

新辅助

2020-05-29

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

J Clin Oncol：新辅助治疗可提高早期直肠癌患者的肛门保留率

2022-11-07

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

NEJM：Cemiplimab用于II 至 IV 期可切除的皮肤鳞状细胞癌的新辅助治疗

2023-03-31

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递

2022-10-17

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

European Radiology：超声弹性成像在预测乳腺癌新辅助化疗后腋窝淋巴结状态中的应用

2023-06-04

柳叶一刀 (审核中...)

前往app查看评论内容

#新辅助#

European Radiology：利用深度学习和基于MRI的放射组学列线图自动预测骨肉瘤的新辅助化疗反应

2023-04-01

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递

2023-06-14

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

乳腺癌治疗领域首个免疫检查点抑制剂惨败：T药联合新辅助双妥+化疗未能改善早期乳腺癌pCR！

2023-02-12

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率

2023-04-30

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

JAMA Oncol：nab-紫杉醇新辅助化疗加用地诺单抗对原发性乳腺癌病理完全缓解率的影响

2023-04-11

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

European Radiology：基于CESM的放射组学在术前预测乳腺癌新辅助化疗效果方面的价值

2022-08-22

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

JAMA Oncol：临界可切除的胰腺导管癌的最佳新辅助治疗策略

2023-05-29

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

European Radiology：超快速动态增强乳腺MRI在乳腺癌新辅助治疗与病理完全缓解中的应用

2022-11-12

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究

2022-07-03

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响

2023-01-05

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果

2023-03-14

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

European Radiology:平扫MRI定量参数在早期预测乳腺癌新辅助化疗病理反应中的价值

2022-08-09

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

European Radiology：MRI对新辅助化疗乳腺癌患者病理完全缓解的预测

2022-04-10

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）

2022-02-27

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

辅助治疗和新辅助治疗加用免疫治疗在可切除性非小细胞肺癌中的疗效

2023-05-09

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

J Clin Oncol：纳武单抗/伊匹单抗新辅助治疗+纳武单抗辅助治疗dMMR/MSI-H胃/胃食管交界腺癌

2023-06-30

科室
- - 订阅+
  - 更多科室
工具
服务